- Home
- Companies
- Camurus AB
- Products
- Camurus - Model CAM2029 - Somatostatin ...
Camurus - Model CAM2029 - Somatostatin Analogues Treatment
Camurus` clinical pipeline represents a healthy mix of in-house and partnered programs from early to late stage development. Our innovative product candidates are designed to address important unmet medical needs, with the potential to make a significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery.
CAM2029 is developed for the treatment of acromegaly and neuroendocrine tumors. The product candidate offers important potential advantages over current marketed products, including easy administration, significantly increased bioavailability, and potential for enhanced treatment efficacy in patients for whom current treatments provide suboptimal treatment effects.
CAM2029 is a ready-to-use, long-acting subcutaneous injection depot based on the active substance octreotide formulated with Camurus` proprietary FluidCrystal® injection depot technology. It is provided as a prefilled syringe, thus not requiring any reconstitution or conditioning prior to administration. Due to the superior ease of handling and administration, CAM2029 can be conveniently administered by the patients’ themselves.
CAM2029 – Key target attributes
- Subcutaneous long-acting octreotide
- Fast onset and one month duration of therapeutic plasma-levels
- Provided ready-for-use in prefilled syringes for easy self-administration
- Compatible with autoinjectors
- High bioavailability – 500% higher than Sandostatin® LAR®, with potential for better treatment effects in some patients
CAM2029 - Key publications
- Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study
- Pavel M, Borson‑Chazot F, Cailleux A, Hörsch D, Lahner H, Pivonello R, Tauchmanova L, Darstein C, Olsson H, Tiberg F, Ferone D., Cancer Chemotherapy and Pharmacology (2019) 83:375–385